SCHEDULE: Neil Johnson Discloses 6.2% Stake in Syra Health Corp

Neil Johnson has reported a 6.2% beneficial ownership stake in Syra Health Corp, acquired with personal funds for the purpose of influence.

Summary

• Neil Johnson has filed a Schedule 13D, disclosing beneficial ownership of 700,312 shares of Syra Health Corp's Class A Common Stock.
• This ownership represents 6.2% of the company's outstanding Class A Common Stock.
• The shares were acquired using personal funds.
• The stated purpose of the transaction is to 'Influence' Syra Health Corp.
• A specific transaction on January 13, 2026, involved the acquisition of 38,182 shares at $0.085 per share by Neil Johnson.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and intent, which is neutral in itself. The stated purpose of 'Influence' introduces a dynamic element that could be interpreted positively or negatively depending on future actions, thus a neutral score is appropriate at this stage.

Risks

• The stated purpose of the transaction is to 'Influence' Syra Health Corp, which could lead to potential changes in corporate strategy, management, or operations, potentially causing uncertainty.

Future Outlook

The filing indicates Neil Johnson's intent to 'Influence' Syra Health Corp, suggesting potential future engagement or strategic shifts, though no specific forward-looking plans are detailed.

Industry Context

This filing represents a significant individual investor taking a notable stake in a publicly traded company, a common occurrence that can sometimes precede activist campaigns or strategic shifts, depending on the nature and extent of the intended 'influence'.

Stakeholder Impact

• Shareholders may react to the disclosure of a new significant owner with an explicit intent to 'Influence' the company, potentially leading to speculation about future strategic directions or management changes.
• Current management and the board of directors may need to engage with Neil Johnson to understand the scope and nature of his intended influence.

Next Steps

• Monitor for further disclosures or announcements regarding Neil Johnson's engagement with Syra Health Corp, particularly concerning the nature and extent of his intended 'influence'.

Key Dates

Recommendation

The disclosure of a 6.2% stake by an individual investor with the stated purpose to 'Influence' Syra Health Corp introduces a new dynamic. While this could lead to positive strategic developments, it also carries the potential for uncertainty or disagreement with current management. Investors should 'hold' to observe how this influence manifests and its potential impact on the company's strategy and performance before making further investment decisions.

Keywords

Syra Health Corp, Neil Johnson, Schedule 13D, Beneficial Ownership, Class A Common Stock, Shareholder Activism, Influence, Equity Stake